ReviewNanotheranostics2026
Next-Generation Anticancer Peptides: Engineering, Nanotheranostics and Clinical Translation.
Review in Nanotheranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Anticancer peptides (ACPs) have emerged as a transformative class of next-generation therapeutics that bridge molecular precision with multifunctional tunability. Unlike many conventional small molecule chemotherapeutics, ACPs offer intrinsic selectivity toward malignant cells through preferential membrane targeting, immunomodulation, and disruption of oncogenic signalling pathways. Advances in peptide engineering, including sequence optimization, incorporation of non-natural amino acids, cyclization, stapling, PEGylation, and structure-activity relationship-guided refinement, have substantially improved their stability, potency, and pharmacokinetic performance. Parallel progress in nanotechnology has further expanded the translational potential of ACPs by enabling controlled release, cancer cell specific targeting, and multimodal theranostic integration. Lipid nanoparticles, solid lipid nanoparticles, polymeric systems, dendrimers, mesoporous silica nanoparticles, and stimuli-responsive platforms now provide multiple and combinatorial strategies to overcome biological barriers, enhance intracellular delivery, and minimize systemic toxicity. Emerging concepts such as enzyme-activated nanocarriers, ligand-directed precision delivery, and light- or pH-responsive systems are redefining and energizing the spatial and temporal control of peptide therapeutics research fields. Despite encouraging preclinical and early clinical progress, including FDA-approved peptide-based agents and peptide receptor radionuclide therapies, challenges related to stability, immunogenicity, manufacturing scalability, and regulatory harmonization remain significant. This review highlights current advances in ACP discovery, molecular engineering, and nanotheranostic integration, and outlines a roadmap for advancing peptide-based precision oncology. Collectively, next-generation ACP platforms hold promise to reshape cancer therapy by integrating targeted cytotoxicity, immune activation, and real-time imaging within a single modular framework.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.